Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 8151 - 8175 of 8297 in total
Investigational
Investigational
Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.[L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
Investigational
Investigational
Opaganib, also known as ABC294640, is a selective sphingosine kinase-2 (SK2) (https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19.
Investigational
Investigational
Experimental
A MET receptor tyrosine kinase inhibitor.
Investigational
Investigational
TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
A P2Y12 inhibitor and platelet aggregation inhibitor.
Investigational
Investigational
rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Investigational
Investigational
Investigational
Investigational
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
AR-9281 inhibits soluble epoxide hydrolase.
Investigational
Investigational
Investigational
Displaying drugs 8151 - 8175 of 8297 in total